NR3C2 and Hyperkalemia: We did not evaluate the usage of sodium-glucose cotransporter 2 inhibitors ornonsteroidal mineralocorticoid receptor antagonists, which emerged as beneficialmedications in trials that were conducted during and after our study.42, , , -46 The challenges with usingthese medications may be similar to those for ACE-I/ARBs, as these medications alsocontribute to a temporary rise in the serum creatinine and/or hyperkalemia.Consequently, an elevated discharge serum creatinine may also be a barrier toprescribing these medications in survivors of AKI similar to what we observed withACE-I/ARB therapy.